Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress
Krakow, Poland – 11 June, 2021 – Ryvu Therapeutics [WSE:RVU] today announced the online publication of two posters and an oral presentation demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 (previously SEL120) and the dual PIM/FLT3 inhibitor SEL24 (MEN1703), in-licensed by Menarini Group from Ryvu Therapeutics, at the Annual European Hematology Association (EHA) 2021 Virtual Congress.
Poster Presentation:
Session Title: Oral Session: Correlating mutations with phenotype in MDS
Title: RVU120/SEL120 CDK8/19 inhibitor – a drug candidate for the treatment of MDS can induce erythroid differentiation in transformed CD34+ hematopoietic progenitor cells
- Abstract #: S164
Session Title: Poster Session: Acute myeloid leukemia - Clinical
Title: CLI120-001 Phase1b Study of SEL120/RVU120 in patients with AML or High Risk MDS: Preliminary clinical and PK results from initial dose escalation cohorts
- Abstract #: EP480
In addition, a clinical abstract regarding the First in Human study of dual PIM/FLT3 inhibitor SEL24(MEN1703) conducted by Ryvu’s partner Menarini Group, has also been accepted for a poster presentation at the upcoming EHA Congress.